Trials / Completed
CompletedNCT02402764
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
Investigator-Initiated Phase 2 Clinical Trial of Selinexor (KPT-330) for the Treatment of Metastatic Triple Negative Breast Cancer
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 10 (actual)
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose of this study is to see whether the combination of selinexor (KPT-330) can help people with triple negative breast cancer (TNBC). Researchers also want to study the safety and tolerability of Selinexor in TNBC patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Selinexor | Participants will receive selinexor twice weekly on Monday/Wednesday, Tuesday/Thursday or Wednesday/Friday of Weeks 1, 2 and 3 of each 4-week cycle. Selinexor will not be taken during Week 4. One cycle is defined as 28 days or 6 doses. The starting dose for this trial is 60 mg (flat dose as long as their dose-based body surface area (BSA) analysis does not exceed 70 mg/m\^2). |
Timeline
- Start date
- 2015-07-08
- Primary completion
- 2016-03-10
- Completion
- 2019-06-06
- First posted
- 2015-03-30
- Last updated
- 2020-09-11
- Results posted
- 2017-03-30
Locations
1 site across 1 country: United States
Source: ClinicalTrials.gov record NCT02402764. Inclusion in this directory is not an endorsement.